Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis
Authors:
- Patricia J. McLaughlinPMPatricia J. McLaughlin
- Ian S. ZagonIZIan S. Zagon
- 1 March 2011
- journal article
- Published by Elsevier in Brain Research
- Vol. 1381, 243-253
Abstract
No abstract availableKeywords
Funding Information
- National Multiple Sclerosis Society
This publication has 49 references indexed in Scilit:
- B lymphocyte proliferation is suppressed by the opioid growth factor–opioid growth factor receptor axis: Implication for the treatment of autoimmune diseasesImmunobiology, 2011
- Endogenous Opioids Regulate Expression of Experimental Autoimmune Encephalomyelitis: A New Paradigm for the Treatment of Multiple SclerosisExperimental Biology and Medicine, 2009
- Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple SclerosisClinical Neuropharmacology, 2009
- Dependence on Nuclear Localization Signals of the Opioid Growth Factor Receptor in the Regulation of Cell ProliferationExperimental Biology and Medicine, 2009
- The OGF–OGFr Axis Utilizes the p16INK4aand p21WAF1/CIP1Pathways to Restrict Normal Cell ProliferationMolecular Biology of the Cell, 2009
- Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosisProceedings of the National Academy of Sciences, 2007
- Increased Epitope-Specific CD8+T Cells Prevent Murine Coronavirus Spread to the Spinal Cord and Subsequent DemyelinationJournal of Virology, 2005
- Phosphorylation of enkephalins enhances their proteolytic stabilityLife Sciences, 1996
- Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: A role for endogenous opioid systems in cancerLife Sciences, 1984
- Elevated plasma β-endorphin levels in pregnant women and their neonatesLife Sciences, 1979